- Home
- JKHY vs BMRN Comparison
JKHY vs BMRN Comparison
Compare JKHY & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JKHY
- BMRN
- Stock Information
- Founded
- JKHY 1976
- BMRN 1996
- Country
- JKHY United States
- BMRN United States
- Employees
- JKHY N/A
- BMRN N/A
- Industry
- JKHY Retail: Computer Software & Peripheral Equipment
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- JKHY Technology
- BMRN Health Care
- Exchange
- JKHY Nasdaq
- BMRN Nasdaq
- Market Cap
- JKHY 12.1B
- BMRN 13.7B
- IPO Year
- JKHY N/A
- BMRN 1999
- Fundamental
- Price
- JKHY $171.83
- BMRN $59.17
- Analyst Decision
- JKHY Hold
- BMRN Buy
- Analyst Count
- JKHY 10
- BMRN 22
- Target Price
- JKHY $186.80
- BMRN $94.00
- AVG Volume (30 Days)
- JKHY 645.8K
- BMRN 2.0M
- Earning Date
- JKHY 05-06-2025
- BMRN 05-01-2025
- Dividend Yield
- JKHY 1.35%
- BMRN N/A
- EPS Growth
- JKHY 8.62
- BMRN 153.71
- EPS
- JKHY 5.55
- BMRN 2.21
- Revenue
- JKHY $2,273,303,000.00
- BMRN $2,853,915,000.00
- Revenue This Year
- JKHY $9.18
- BMRN $12.23
- Revenue Next Year
- JKHY $7.28
- BMRN $9.93
- P/E Ratio
- JKHY $30.96
- BMRN $26.81
- Revenue Growth
- JKHY 5.23
- BMRN 17.97
- 52 Week Low
- JKHY $157.00
- BMRN $52.93
- 52 Week High
- JKHY $196.00
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- JKHY 45.54
- BMRN 37.64
- Support Level
- JKHY $165.68
- BMRN $52.93
- Resistance Level
- JKHY $175.79
- BMRN $60.93
- Average True Range (ATR)
- JKHY 6.50
- BMRN 3.18
- MACD
- JKHY -0.44
- BMRN -0.53
- Stochastic Oscillator
- JKHY 38.11
- BMRN 34.01
About JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for us banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.